{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.61","value":"-0.2"},{"groupId":"OG001","spread":"0.61","value":"-0.2"}]}],"title":"Week 1, n=228, 440"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.67","value":"-0.2"},{"groupId":"OG001","spread":"0.65","value":"-0.3"}]}],"title":"Week 2, n=225, 436"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.72","value":"-0.3"},{"groupId":"OG001","spread":"0.84","value":"-0.4"}]}],"title":"Week 4, n=216, 427"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.78","value":"-0.4"},{"groupId":"OG001","spread":"0.80","value":"-0.4"}]}],"title":"Week 6, n=196, 418"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.89","value":"-0.4"},{"groupId":"OG001","spread":"0.92","value":"-0.6"}]}],"title":"Week 8, n=189, 413"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.11","value":"-0.5"},{"groupId":"OG001","spread":"1.09","value":"-0.8"}]}],"title":"Week 12, n=164, 401"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.10","value":"-0.7"},{"groupId":"OG001","spread":"1.14","value":"-1.0"}]}],"title":"Week 16, n=138, 375"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.24","value":"-0.7"},{"groupId":"OG001","spread":"1.27","value":"-1.2"}]}],"title":"Week 20, n=134, 362"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.19","value":"-0.6"},{"groupId":"OG001","spread":"1.42","value":"-1.5"}]}],"title":"Week 24, n=87, 248"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.63","value":"-0.9"},{"groupId":"OG001","spread":"1.42","value":"-1.6"}]}],"title":"Week 28, n=73, 201"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.25","value":"-0.7"},{"groupId":"OG001","spread":"1.46","value":"-1.5"}]}],"title":"Week 32, n=68, 183"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.30","value":"-0.7"},{"groupId":"OG001","spread":"1.51","value":"-1.6"}]}],"title":"Week 36, n=67, 174"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.42","value":"-0.7"},{"groupId":"OG001","spread":"1.59","value":"-1.6"}]}],"title":"Week 40, n=63, 169"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.53","value":"-0.8"},{"groupId":"OG001","spread":"1.61","value":"-1.7"}]}],"title":"Week 44, n=64, 166"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.33","value":"-0.7"},{"groupId":"OG001","spread":"1.66","value":"-1.5"}]}],"title":"End of Treatment, n=212, 416"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.37","value":"-0.7"},{"groupId":"OG001","spread":"1.66","value":"-1.3"}]}],"title":"4-week FU, n=202, 402"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.54","value":"-0.5"},{"groupId":"OG001","spread":"1.79","value":"-1.0"}]}],"title":"12-week FU, n=196, 398"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.81","value":"-0.3"},{"groupId":"OG001","spread":"1.78","value":"-0.6"}]}],"title":"24-week FU, n=195, 390"}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"440"}],"units":"Participants"}],"description":"The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=90 Gi/L) in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"MEAN","populationDescription":"Safety DB Population. Only those participants contributing data at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)","title":"Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase","type":"SECONDARY","unitOfMeasure":"Kilograms per meters squared (kg/m^2)"}